Compositions and methods for treating motor disorders

Abstract

This invention provides methods utilizing ketamine for the treatment of motor disorders and/or side effects associated with certain medications used in the treatment of motor disorders. For example, in some embodiments, methods are provided for treating side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering a dose of ketamine or a pharmaceutically acceptable salt thereof. In particular, the invention provides methods for reducing dyskinesia associated with motor disorder (e.g., Parkinson's disease) treatments, and effective doses of ketamine or a pharmaceutically acceptable salt

We claim: 
     
         1 . (canceled) 
     
     
         2 . A method of attenuating and/or treating a human patient suffering from dyskinesia, comprising administering to the human patient within a ten-day period two or more doses of a composition comprising a dose of ketamine or a pharmaceutically acceptable salt thereof,
 wherein each dose is at least a two hour administration of 0.15 mg/kg/hour to about 2 mg/kg/hour of ketamine or a pharmaceutically acceptable salt thereof.   
     
     
         3 . The method of  claim 2 , wherein the dyskinesia is levodopa induced dyskinesia. 
     
     
         4 . The method of  claim 2 , wherein each of the doses are administered via infusion delivery, intranasal delivery, transdermal delivery, oral delivery, or intravenous delivery. 
     
     
         5 . The method of  claim 2 , wherein administering the composition results in the patient experiencing chemical-induced deep brain stimulation. 
     
     
         6 . The method of  claim 5 , wherein the chemical-induced deep brain stimulation results in attenuation and/or treating of the symptoms of the dyskinesia. (New) The method of  claim 2 , further comprising administration of carbidopa. 
     
     
         8 . The method of  claim 2 , wherein the human subject is suffering from Parkinson's disease. 
     
     
         9 . The method of  claim 2 , wherein the at least two hour administration is at least three hours. 
     
     
         10 . The method of  claim 2 , wherein the at least two hour administration is at least four hours. 
     
     
         11 . The method of  claim 2 , wherein the at least two hour administration is at least five hours. 
     
     
         12 . The method of  claim 2 , wherein the at least two hour administration is at least six hours. 
     
     
         13 . The method of  claim 2 , wherein the at least two hour administration is at least seven hours. 
     
     
         14 . The method of  claim 2 , wherein the at least two hour administration is at least eight hours. 
     
     
         15 . The method of  claim 2 , wherein the at least two hour administration is at least nine hours. 
     
     
         16 . The method of  claim 2 , wherein the at least two hour administration is at least ten hours. 
     
     
         17 . The method of  claim 2 , wherein the within a ten-day period is within 72 hours 
     
     
         18 . The method of  claim 2 , wherein ketamine is a metabolite of ketamine, wherein the metabolite of ketamine is selected from R-norketamine (NK), R-dehydronorketamine (DHK), S-norketamine (NK), S-dehydronorketamine (DHK), (2R,6R)-hydroxynorketamine (HNK), and (2S,6S)-hydroxynorketamine (HNK). 
     
     
         19 . A device for attenuating and/or treating a human patient suffering from dyskinesia, wherein the device is configured to deliver to the human patient over at least a two hour period a dose of about 0.15 mg/kg/hour to about 2 mg/kg/hour of ketamine or a pharmaceutically acceptable salt thereof. 
     
     
         20 . The device of  claim 2 , wherein the device is configured for transdermal delivery of the dose, infusion delivery of the dose, intranasal delivery of the dose, oral delivery of the dose, or intravenous delivery of the dose.